What we are looking for

We are seeking project proposals which have the potential to address the TPPs identified, in particular:

• • Antimicrobials focused on Pseudomonas aeruginosa infections as 1) a maintenance therapy to suppress chronic respiratory infection or 2) treatment of acute pulmonary exacerbations linked to Pseudomonas aeruginosa infection.

  • Antimicrobials focused on Mycobacterium abscessus infections as 1) a maintenance therapy to suppress chronic respiratory infection or 2) treatment of acute pulmonary exacerbations linked to M.abscessus infection, or 3) eradication treatment. Also, in scope treatments targeting ‘fast-growing’ NTMs of the M.abscessus complex esp. those resistant to existing standard of care (Macrolides) and antimicrobials to Mycobacterium avium.

  • Antimicrobials focused on treating infections associated with other emerging pathogens associated with CF; Strenotrophomonas maltophilia, H.influenzae, B.cepacia (and related species such as B.cenocepacia, B. multivorans), Achromobacter spp. Pandoraea spp, Ralstonia spp, S. aureus. Treatments to fungal pathogens associated with chronic infections in CF (Aspergillus, Candida albicans) are also considered in scope.

The CF AMR Syndicate intend to fund projects which:

• • Are early-phase antimicrobial projects from hit validation through lead optimisation and early preclinical

  • Projects with a clear value proposition, clinical positioning, and identification/engagement of follow-on funding

  • Projects can be of varying modalities of intervention (e.g., small and large molecule, phage etc.), either direct-acting and otherwise (e.g., anti-virulence)

We are not looking for:

• • Projects focused solely on IND/CTA-enabling studies or clinical phase R&D

  • Target identification

  • Projects not directly focused on antimicrobial development (e.g., diagnostics, drug delivery, biomarkers)